Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.40−0.05 (-10.74%)
Close on Nov 17, 2026Market cap $110.95MP/E –Yield –
Akebia Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Akebia Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $41.55M. For fiscal 2025 it was $67.99M. The highest annual figure on record is $67.99M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.99M | – |
| FY2024 | Dec 31, 2024 | -$40.66M | – |
| FY2023 | Dec 31, 2023 | -$23.38M | – |
| FY2022 | Dec 31, 2022 | -$73.15M | – |
| FY2021 | Dec 31, 2021 | -$252.97M | – |
| FY2020 | Dec 31, 2020 | -$110.39M | – |
| FY2019 | Dec 31, 2019 | -$257.44M | – |
| FY2018 | Dec 31, 2018 | -$97.49M | – |
| FY2017 | Dec 31, 2017 | -$56.16M | -197.0% |
| FY2016 | Dec 31, 2016 | $57.91M | – |
| FY2015 | Dec 31, 2015 | -$52.41M | – |
| FY2014 | Dec 31, 2014 | -$27.48M | – |
| FY2013 | Dec 31, 2013 | -$11.33M | – |
| FY2012 | Dec 31, 2012 | -$7.21M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.53M | -84.2% |
| Q1 FY2026 | Mar 31, 2026 | -$21.21M | – |
| Q4 FY2025 | Dec 31, 2025 | $31.13M | – |
| Q3 FY2025 | Sep 30, 2025 | $28.11M | – |
| Q2 FY2025 | Jun 30, 2025 | $22.35M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.07M | -377.4% |
| Q1 FY2024 | Mar 31, 2024 | -$19.43M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.17M | -121.2% |
| Q2 FY2023 | Jun 30, 2023 | $3.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.54M | – |
| Q4 FY2022 | Dec 31, 2022 | -$54.68M | – |
| Q3 FY2022 | Sep 30, 2022 | $33.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.66M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$62.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$56.27M | – |
| Q2 FY2021 | Jun 30, 2021 | -$63.14M | -269.6% |
| Q1 FY2021 | Mar 31, 2021 | -$70.75M | – |
| Q4 FY2020 | Dec 31, 2020 | -$30.78M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.24M | -347.9% |
| Q2 FY2020 | Jun 30, 2020 | $37.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$89.59M | – |
| Q4 FY2019 | Dec 31, 2019 | -$92.14M | – |
| Q3 FY2019 | Sep 30, 2019 | $10.99M | – |
| Q2 FY2019 | Jun 30, 2019 | -$38.37M | -526.5% |
| Q1 FY2019 | Mar 31, 2019 | -$137.93M | – |
| Q4 FY2018 | Dec 31, 2018 | -$73.70M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.46M | – |
| Q2 FY2018 | Jun 30, 2018 | $9.00M | -63.1% |
| Q1 FY2018 | Mar 31, 2018 | -$20.33M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.38M | -117.1% |
| Q3 FY2017 | Sep 30, 2017 | -$54.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $24.36M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.53M | – |
| Q4 FY2016 | Dec 31, 2016 | $95.67M | – |
| Q3 FY2016 | Sep 30, 2016 | -$28.24M | – |
See a number that looks wrong?